YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Global bond markets have been hit hard recently, with the UK 30-year gilt yield touching 6%, which is the highest level since 1998. Higher borrowing costs can pressure many sectors, but they often push investors toward businesses seen as e…
HUTCHMED (China) Limited — Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after progression on an EGFR-TKI therapy — — Application supported by…
HUTCHMED (China) Limited First-in-class KRAS-payload leveraging synchronized EGFR inhibition HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 27, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/A…
On September 3, HUTCHMED (China) Limited (NASDAQ:HCM) announced an exclusive global development and licensing agreement with GSK plc (NYSE:GSK) for HMPL-A830, targeting colorectal, pancreatic, and lung cancers. Under the agreement, HUTCHME…
HUTCHMED (China) Limited HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of…
[Stock market data with uptrend vector] sitox * Shares in Chinese biopharma stocks rose on Monday, with Innovent Biologics (IVBIY [https://seekingalpha.com/symbol/IVBIY]) rising 7% and Akeso (AKESF) up 8% after a report that the U.S. may a…
Key Points Interested in HUTCHMED (China) Limited Sponsored ADR? Here are five stocks we like better. HUTCHMED signed a deal with GSK worth up to approximately $1.3 billion for ex-China rights to HMPL-A830, including a $110 million upfront…
Panmure and Cavendish reiterate buy on Hutchmed after GSK deal Proactive uses images sourced from Shutterstock Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) won ringing endorsements from City brokers on Thursday after secu…
* HUTCHMED (HCM [https://seekingalpha.com/symbol/HCM]) said [https://seekingalpha.com/pr/20639242-hutchmed-announces-licensing-agreement-with-gsk-for-kras-egfr-antibody-conjugate-cancer] it signed an exclusive licensing deal with GSK (GSK…
HUTCHMED (China) Limited — Exclusive License for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate ("ATTC"), which is expected to enter clinical trials in H2 2026 — — HUTCHMED webcasts today at 4:30 p.m. HKT in Chin…
HUTCHMED (China) Limited Findings build on the established success of the global SAFFRON and China SACHI trials, extending the clinical value of the all-oral combination into the first-line setting HONG KONG and SHANGHAI and FLORHAM PARK,…
HUTCHMED (China) Limited Novel, highly potent oral selective FGFR 1/2/3 inhibitor approved for patients with advanced FGFR2-altered intrahepatic cholangiocarcinoma in China HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 27, 2026 (GLOB…
AstraZeneca AZN announced that it is discontinuing a phase III study called eVOLVE-Lung02, evaluating its experimental bispecific antibody, volrustomig, in certain patients with non-small cell lung cancer (NSCLC). The late-stage study asse…
HUTCHMED (China) Limited — First global Phase III trial to show significant progression-free and overall survival benefits in this setting — — SAFFRON trial results reinforce TAGRISSO® as the backbone therapy across EGFRm lung cancer — HON…
This article first appeared on GuruFocus. Release Date: July 30, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Strong China product sales growth, with Elunate and…
Key Points Interested in HUTCHMED (China) Limited Sponsored ADR? Here are five stocks we like better. HUTCHMED remained profitable in H1 2026, reporting $162 million in oncology revenue, up 23% year over year, and $16 million in net income…
HUTCHMED (China) Limited — China product sales recovery continues led by ELUNATE® and SULANDA® with over 40% growth each — — FRUZAQLA® ex-US sales driving growth – now approved or launched in 41 countries — — Strong progress in ATTCs, a so…
HUTCHMED (China) Limited First selective MET inhibitor approved for patients with MET-amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma in China HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 02, 2026 (GLOB…
HUTCHMED (China) Limited HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months ended June 30,…
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months ended June 30, 2026 on Thursday, July 30…
(RTTNews) - HUTCHMED (China) Limited (HCM), a commercial-stage biotechnology company, announced that the pivotal Phase 2 registrational study of Fanregratinib met its primary endpoint in the treatment of Intrahepatic Cholangiocarcinoma. Fa…
HUTCHMED (China) Limited — Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control — — Fanregratinib holds promise as a new treatment option for pretreated advanc…
— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control — — Fanregratinib holds promise as a new treatment option for pretreated advanced ICC patients harboring…
(RTTNews) - HUTCHMED (China) Limited (HCM), a commercial-stage biopharmaceutical company, announced on Friday results from the Phase III portion of the ESLIM-02 study of Sovleplenib in patients with warm antibody autoimmune hemolytic anaem…
HUTCHMED (China) Limited — Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile — —The ESLIM-02 study underscores sovleplenib's potential to address critical unmet needs in a treatment landscape curr…
— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile — —The ESLIM-02 study underscores sovleplenib’s potential to address critical unmet needs in a treatment landscape currently devoid of approved…
We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. HUTCHMED (China) Limited (NASDAQ:HCM) is one of the most undervalued pharma stocks. TheFly reported on May 28 that Morgan Stanley upgraded HCM to Equal Weig…
(Bloomberg) -- HSBC Holdings Plc is redoubling efforts to revive its flagging Hong Kong investment banking franchise, deploying its top leadership to win back market share as competition intensifies in Asia’s biggest financial hub. Most Re…
HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be p…
(RTTNews) - HUTCHMED (HCM) and Innovent Biologics, Inc (HKEX:1801) said the China National Medical Products Administration (NMPA) has approved the combination of ELUNATE (fruquintinib) and TYVYT (sintilimab injection) for patients with loc…
HUTCHMED (China) Limited Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (Chin…
Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study SAN FRANCISCO and SUZHOU, China, May 21, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a wo…
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”, HKEX:1801) today jointly announce that the New Drug A…
Virtual Investor Conferences Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference seri…
HUTCHMED (China) Limited HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for sovlepleni…
Virtual Investor Conferences NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Tuesday, April 28, 2026 featuring live webcast presenta…